REG - Hikma Pharmaceutical - Block listing Interim Review

Hikma PharmaceuticalsAnnouncement

01/04/2022 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220401:nRSA0483Ha&default-theme=true

RNS Number : 0483H  Hikma Pharmaceuticals Plc  01 April 2022

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 1 April 2022

 

 Name of applicant:                                                            Hikma Pharmaceuticals PLC
 Name of scheme:                                                               Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 Period of return                                                              From: 1 October 2021  To:                  31 March 2022
 Balance of unallotted securities under scheme(s) from previous return:        SOP: 792,700 Ordinary Shares of 10 pence
 Plus:  The amount by which the block scheme(s) has been increased since the   SOP: 0 Ordinary Shares of 10 pence
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period     SOP: 0 Ordinary Shares of 10 pence
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:    SOP: 792,700 Ordinary Shares of 10 pence

 

 Name of contact:              Peter Speirs
 Telephone number of contact:  0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 1 April 2022

 

 Name of applicant:                                                            Hikma Pharmaceuticals PLC
 Name of scheme:                                                               Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")
 Period of return                                                              From: 1 October 2021    To:                     31 March 2022
 Balance of unallotted securities under scheme(s) from previous return:        LTIP: 57,502 Ordinary Shares of 10 pence
 Plus:  The amount by which the block scheme(s) has been increased since the   LTIP: 0 Ordinary Shares of 10 pence
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period     LTIP: 0 Ordinary Shares of 10 pence
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:    LTIP: 57,502 Ordinary Shares of 10 pence

 

 Name of contact:              Peter Speirs
 Telephone number of contact:  0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 April 2022

 

 Name of applicant:                                                            Hikma Pharmaceuticals PLC
 Name of scheme:                                                               Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")
 Period of return                                                              From: 1 October 2021      To:                       31 March 2022
 Balance of unallotted securities under scheme(s) from previous return:        2009 MIP: 0 Ordinary Shares of 10 pence
 Plus:  The amount by which the block scheme(s) has been increased since the   2009 MIP: 0 Ordinary Shares of 10 pence
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period     2009 MIP: 0 Ordinary Shares of 10 pence
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:    2009 MIP: 0 Ordinary Shares of 10 pence

 

 Name of contact:              Peter Speirs
 Telephone number of contact:  0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 April 2022

 

 Name of applicant:                                                            Hikma Pharmaceuticals PLC
 Name of scheme:                                                               Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP")
 Period of return                                                              From: 1 October 2021      To:                       31 March 2022
 Balance of unallotted securities under scheme(s) from previous return:        2018 MIP: 773,494 Ordinary Shares of 10 pence
 Plus:  The amount by which the block scheme(s) has been increased since the   2018 MIP: 0 Ordinary Shares of 10 pence
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period     2018 MIP: 345,294 Ordinary Shares of 10 pence
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:    2018 MIP: 428,200 Ordinary Shares of 10 pence

 

 Name of contact:              Peter Speirs
 Telephone number of contact:  0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 April 2022

 

 Name of applicant:                                                            Hikma Pharmaceuticals PLC
 Name of scheme:                                                               Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")
 Period of return                                                              From: 1 October 2021    To:                     31 March 2022
 Balance of unallotted securities under scheme(s) from previous return:        EIP: 1,249,533 Ordinary Shares of 10 pence
 Plus:  The amount by which the block scheme(s) has been increased since the   EIP: 0 Ordinary Shares of 10 pence
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period     EIP: 791,344 Ordinary Shares of 10 pence
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:    EIP: 458,189 Ordinary Shares of 10 pence

 

 Name of contact:              Peter Speirs
 Telephone number of contact:  0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUPUACCUPPGQG